Pilot study of oral metformin in cancer-bearing cats
| Autor: | Jackie M. Wypij |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Male Vascular Endothelial Growth Factor A medicine.medical_specialty Administration Oral Antineoplastic Agents Pilot Projects Anorexia Cat Diseases Gastroenterology Asymptomatic 03 medical and health sciences 0302 clinical medicine Internal medicine Neoplasms medicine Animals Insulin-Like Growth Factor I CATS General Veterinary medicine.diagnostic_test business.industry Complete blood count medicine.disease Metformin Surgery 030104 developmental biology 030220 oncology & carcinogenesis Lactic acidosis Vomiting Cats Hyperlactatemia Female medicine.symptom business medicine.drug |
| Zdroj: | Veterinary and comparative oncology. 15(2) |
| ISSN: | 1476-5829 |
| Popis: | A prospective dose escalation pilot study was performed in cancer-bearing cats to assess toxicity and surrogate biomarkers of pharmacologic activity of oral metformin hydrochloride. Nine cats with measurable spontaneous cancer were treated with oral metformin for 14 days. Monitoring included complete blood count (CBC), serum biochemistry, lactate, pH, insulin-like growth factor-1, and vascular endothelial growth factor serially until study completion. At the maximum tolerated dose of 10 mg kg-1 q12 h side effects were primarily mild to moderate gastrointestinal upset (anorexia, vomiting, and/or weight loss). All cats developed a reduction in haematocrit. Six of nine cats developed new or progressive hyperlactatemia and one cat developed asymptomatic lactic acidosis. There were no clinical responders and two cats had modest measurable reduction in tumour size. In conclusion, we demonstrate potential pharmacologic activity of metformin at a clinically relevant dose and identify parameters for clinical monitoring and supportive care. Further investigation of metformin in cancer-bearing cats is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text